Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis
Authors' conclusion
We did not detect clear differences in first remission and sustained remission between participants with RA initiating ETA-B or ETA-O.
Study context
- Population
- Etanercept-naive participants with rheumatoid arthritis (RA) from four Canadian prospective cohorts initiating etanercept biosimilar (ETA-B) or ETA-O (Jan/2015-May/2022)ETA-B: 65.3%
- Participants
- 150 participants
- Exposure
- Etanercept biosimilar vs etanercept originator
- Outcome
- Time to first remission and prevalence of sustained remission (≥2 consecutive visits in remission within first 12 months)
Methodological detailsfour Canadian prospective cohorts, real-world, interim analysis, multivariate Cox regression, multivariate logistic regression
- Four Canadian prospective cohorts
- Real-world
- Interim analysis
- Multivariate Cox regression
- Multivariate logistic regression
Main finding
As reported in the abstract
Time to first remission (125 not in remission at baseline)
AHR for achieving first remission
1.52
95% CI 0.68–3.39
By group
ETA-Bvs ETA-O
aHR for achieving first remission 1.52 (95% CI 0.68–3.39)
Observational data: associations, not effects.
Further findings
| Outcome | ETA-B | ETA-O | aOR for achieving sustained remission (95% CI) | |
|---|---|---|---|---|
| Sustained remission (125 with ≥12 months follow-up) · first 12 monthsMultivariate logistic regression; no significant difference | 19.5% | 21.0% | 1.14 (0.29–4.87) | |
| 0.20.5125AOR for achieving sustained remission (log scale) |
Original publication
Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis. Arthritis Res Ther. Published 17 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →